SCHEMBL163725

SCHEMBL163725

COC(=O)c1scc(C)c1N

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.57
KMT2A Q03164 3/20 0.53
MAPT P10636 2/20 0.49
ATM Q13315 2/20 0.49
PKM P14618 1/20 0.49
POLB P06746 2/20 0.48
CYP1A2 P05177 2/20 0.46
CYP3A4 P08684 2/20 0.46
CYP2C19 P33261 1/20 0.46
ALDH1A1 P00352 2/20 0.45
HTR1A P08908 1/20 0.44
SCN1A P35498 1/20 0.44
SCN2A Q99250 1/20 0.44
SCN3A Q9NY46 1/20 0.44
GAA P10253 3/20 0.44
HPGD P15428 2/20 0.44
MEN1 O00255 1/20 0.44
GLA P06280 1/20 0.44
ALOX15 P16050 1/20 0.44
HSD17B10 Q99714 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL10732632 0.98 KDM4E (0.55) KDM4EKMT2AMAPTATMPKM
Acetic Acid SCHEMBL28971363 0.95 KDM4E (0.53) KDM4EKMT2AMAPTATMPKM
Sulfuric Acid SCHEMBL28971359 0.93 KDM4E (0.59) KDM4EKMT2AMAPTATMPKM
SCHEMBL31150256 0.84 KDM4E (0.44) KDM4EKMT2AMAPTATMPKM
SCHEMBL3369562 0.82 KDM4E (0.58) KDM4EKMT2AMAPTATMPKM
SCHEMBL189938 0.81 ALDH1A1 (0.49) KDM4EKMT2AMAPTATMPKM
SCHEMBL27780614 0.81 KDM4E (0.40) KDM4EKMT2AMAPTATMPKM
SCHEMBL23460209 0.81 KDM4E (0.57) KDM4EKMT2AMAPTATMPKM
SCHEMBL3230676 0.81 KDM4E (0.57) KDM4EKMT2AMAPTATMPOLB
SCHEMBL1845347 0.81 KDM4E (0.57) KDM4EKMT2AMAPTATMPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 483 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115806543-A Articaine hydrochloride intermediate and preparation method and application thereof 济南宣正药业有限公司 2023-03-17 CN claimed
CN-217120215-U Heating device for synthesizing 3-amino-4-methylthiophene-2-methyl formate 济南宣正药业有限公司 2022-08-05 CN claimed
CN-106699724-B A method of recycling articaine hydrochloride or in which product from synthesis mother liquid 蚌埠丰原涂山制药有限公司 2019-10-25 CN claimed
CN-108299382-A A kind of preparation method of articaine hydrochloride intermediate 常州沃腾化工科技有限公司 2018-07-20 CN claimed
CN-106699724-A Method for recovering articaine hydrochloride or intermediate products thereof in self-synthetic mother liquor 蚌埠丰原涂山制药有限公司 2017-05-24 CN claimed
EP-2556062-B1 AMIDE DERIVATIVES OF AVENALUMIC ACID, PROCESS FOR PREPARING SAME AND COSMETIC COMPOSITIONS CONTAINING SAME PROD CHIM AUXILIAIRES ET DE SYNTHESE (FR) 2017-01-04 EP claimed
EP-2170872-B1 PROCESS FOR THE PREPARATION OF THE N-(2-CHLORO-4-METHYL-3-THIENYL)-1H- BENZIMIDAZOL-2-AMINE HYDROCHLORIDE AND INTERMEDIATES THEREOF SANOFI AVENTIS US LLC (US) 2010-09-01 EP claimed
US-20100174088-A1 PROCESS FOR THE PREPARATION OF BENZIMIDAZOL THIENYLAMINE COMPOUNDS AND DERIVATIVES THEREOF USEFUL AS SODIUM/PROTON EXCHANGER TYPE 3 INHIBITORS SANOFI-AVENTIS U.S. LLC (US) 2010-07-08 US claimed
EP-2170872-A2 PROCESS FOR THE PREPARATION OF BENZIMIDAZOL THIENYLAMINE COMPOUNDS AND INTERMEDIATES THEREOF Sanofi-Aventis U.S. LLC (US) 2010-04-07 EP claimed
WO-2009006066-A2 PROCESS FOR THE PREPARATION OF BENZIMIDAZOL THIENYLAMINE COMPOUNDS AND INTERMEDIATES THEREOF SANOFI-AVENTIS U.S. LLC (US) 2009-01-08 WO claimed
EP-4747261-A1 AMINOPYRIMIDINE DERIVATIVES AS CYCLIN-DEPENDENT KINASE INHIBITORS Accutar Biotechnology Inc. (US) 2026-05-27 EP disclosed
WO-2026104680-A1 NOVEL SULFONAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2026-05-21 WO disclosed
US-12624023-B2 Sulfonylurea derivatives and uses thereof NodThera Limited (GB) 2026-05-12 US disclosed
EP-3901151-B1 HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF IOMX THERAPEUTICS AG (DE) 2026-04-01 EP disclosed
EP-4713095-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS Chengdu Anticancer Bioscience, Ltd. (CN) 2026-03-25 EP disclosed
EP-0298542-A1 Process for preparing thiophene derivatives SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1989-01-11 EP disclosed
US-4666502-A Herbicidal N-thienyl-chloroacetamides SANDOZ LTD. (CH) 1987-05-19 US disclosed
US-4472425-A FUNGICIDES SANDOZ LTD. (CH) 1984-09-18 US disclosed
US-4442289-A ANTIASTHMA HOFFMANN-LA ROCHE INC. (US) 1984-04-10 US disclosed
US-4376121-A Antiallerigically-active imidazothienopyrimidine derivatives HOFFMANN-LA ROCHE INC. (US) 1983-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100174088-A1 PROCESS FOR THE PREPARATION OF BENZIMIDAZOL THIENYLAMINE COMPOUNDS AND DERIVATIVES THEREOF USEFUL AS SODIUM/PROTON EXCHANGER TYPE 3 INHIBITORS SLC9A3, NHERF1, SLC9A5 KDM4E 1734/4885KMT2A 1001/4885MAPT 4075/4885
US-12624023-B2 Sulfonylurea derivatives and uses thereof PYCARD, NOD1, NLRP3 KDM4E 3454/4885KMT2A 4104/4885MAPT 4223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.